Mesa Laboratories (MLAB) SVP Operations David Sells 2,480 Shares

Brian Archbold, the Senior Vice President of Operations at Mesa Laboratories, Inc. (MLAB), sold 2,480 shares of the company on June 18, 2026. This transaction was disclosed in a recent filing with the Securities and Exchange Commission. The sale was part of a flurry of activity for Archbold, who has been active in the market with several trades over the course of just a few days in mid-June.

Archbold's Shifting Position in MLAB

This latest sale of 2,480 shares is just one piece of a larger puzzle for Archbold. On the very same day, June 18, he also purchased 3,324 shares at a price of $95.10, a transaction worth more than $316,000. He didn't stop there; just a few days later, on June 22, he sold another 2,516 shares at an average price of $89.50, totaling approximately $225,182. None of these transactions were noted as being part of a pre-planned trading schedule.

Other Insider Activity at Mesa Laboratories

Archbold wasn't the only executive moving shares in June. Chief Accounting Officer Lyndsey Elizabeth Crennen was also busy, buying 263 shares on June 18 at $95.10, while simultaneously selling 233 shares that same day. Crennen later sold another 442 shares on June 22 at a price of $89.50, a trade valued at $39,559. Additionally, Chief Financial Officer John Sakys sold 2,756 shares on June 18. This collective movement shows that several members of the leadership team were adjusting their personal holdings during the same window.

Stock Performance and Valuation

On Tuesday, the stock was trading at $93.23. The company has seen its share price fluctuate significantly over the last year, reaching as high as $132.70 and dipping as low as $63.48. Currently, the stock is trading below its 50-day moving average of $112.70 and its 200-day moving average of $97.02. With a price-to-earnings ratio of 155.14, the stock carries a high valuation relative to its current trailing earnings, though its forward P/E ratio — which looks at estimated future profits — is much lower at 12.84.

Recent Earnings and Dividends

Mesa Laboratories reported revenue of $249.72 million in its most recent financial period, showing a modest revenue growth of 0.01%. The company's net margin stands at 1.92%, with a return on equity of 2.66%. Beyond its earnings, the company continues to return value to shareholders through a dividend. It pays an annual dividend of $0.64 per share, which results in a dividend yield of 0.5% at current prices. The payout ratio is 75.29%, meaning a large portion of its earnings is dedicated to these payments.

Analysts Set New Price Targets

Wall Street analysts have provided a mixed but generally stable outlook for the company. On August 14, 2026, Wells Fargo maintained its Equal-Weight rating on the stock but raised its price target to $110.00, up from a previous target of $94.00. Currently, two analysts cover the stock, with a consensus mean price target of $117.50. This suggests analysts see room for the stock to grow from its current levels, even as they maintain a cautious rating.

About Mesa Laboratories

Mesa Laboratories makes and sells high-tech tools used for quality control and life sciences. Their products help pharmaceutical companies and healthcare providers ensure that their sterilization processes work correctly and that their lab results are accurate. Based in Lakewood, Colorado, the company provides everything from protein analysis systems to tools that measure gas flow and torque in manufacturing settings.

What to Watch

Investors should keep an eye on the company's next earnings report, which is scheduled for November 5, 2026. This will provide the next major update on whether the company's growth is accelerating. While the recent insider sales by Archbold and others are notable, they represent only a snapshot in time and may be related to personal financial planning rather than a specific outlook on the company's future performance.